{
  "id": "tesamorelin",
  "name": "Tesamorelin",
  "type": "GHRH Analogue",
  "category": "Growth Hormone",
  "mechanism": "Binds to GHRH receptors in the pituitary, stimulating pulsatile GH release that mimics natural secretion patterns",
  "half_life": "26-38 minutes",
  "dosing": "1-2mg daily, subcutaneous",
  "administration": "Subcutaneous injection",
  "primary_benefits": [
    "Reduction of visceral adipose tissue",
    "Improved triglyceride profiles",
    "Potential cognitive benefits"
  ],
  "research_findings": "Clinical trials demonstrated 15-20% reduction in trunk fat. FDA-approved for HIV-associated lipodystrophy. Currently being studied for mild cognitive impairment",
  "system_targets": [
    "Endocrine",
    "Metabolic"
  ],
  "accessibility": "Prescription required (FDA-approved)",
  "cost_tier": "high"
}